Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Migraine in Adolescence Clear all
Completed Phase 3 Interventional Results available

Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents

NCT00488514
View directory record Official record
Conditions
Migraine Disorders
Interventions
Combination Tablet of Treximet (sumatriptan/naproxen sodium)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 17 Years
Enrollment
656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
77
States / cities
Gilbert, Arizona • Phoenix, Arizona • Jonesboro, Arkansas + 72 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

NCT05127954
View directory record Official record
Conditions
Migraine
Interventions
Ubrogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
109
States / cities
Huntsville, Alabama • Saraland, Alabama • Little Rock, Arkansas + 92 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

Mind and Body Approaches to Pain Reduction in Youth With Migraine

NCT03472092
View directory record Official record
Conditions
Headache, Migraine, Migraine, Migraine Disorders, Headache
Interventions
Cognitive Behavioral Therapy (CBT), Placebo, Amitriptyline, Biofeedback-Assisted Relaxation Training (BART), Cognitive Reappraisal Training (CR)
Behavioral · Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
10 Years to 17 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

NCT03832998
View directory record Official record
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Nitrous Oxide for Acute Migraine Pain in the Emergency Room (ED)

NCT01287052
View directory record Official record
Conditions
Migraine, Pain
Interventions
Nitrous Oxide
Drug
Lead sponsor
Children's Hospitals and Clinics of Minnesota
Other
Eligibility
8 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

A Study Using Botulinum Toxin Type A as Headache Prophylaxis in Adolescents With Chronic Migraine

NCT01662492
View directory record Official record
Conditions
Migraine Disorders
Interventions
Botulinum toxin type A Dose 1, Botulinum toxin type A Dose 2, Placebo (Normal Saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
12 Years to 17 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
22
States / cities
Phoenix, Arizona • Fullerton, California • Oceanside, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Study of Two Digital Therapeutics for the Prevention of Episodic Migraine

NCT05853900
View directory record Official record
Conditions
Migraine, Episodic Migraine, Headache, Headache, Migraine
Interventions
ReMMi-D Digital Therapeutic
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 3 Interventional

SPG Block for Acute Pediatric Migraine

NCT03984045
View directory record Official record
Conditions
Migraine in Children, Sphenopalatine Neuralgia, Migraine in Adolescence
Interventions
Lidocaine topical, Prochlorperazine Injection
Drug
Lead sponsor
Newark Beth Israel Medical Center
Other
Eligibility
10 Years to 20 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of Divalproex Sodium Extended-Release Tablets in Migraine Prophylaxis: A Study in Adolescents

NCT00195741
View directory record Official record
Conditions
Migraine
Interventions
divalproex sodium
Drug
Lead sponsor
Abbott
Industry
Eligibility
12 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
North Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 7, 2007 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting Phase 3 Interventional

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

NCT04965675
View directory record Official record
Conditions
Chronic Migraine in Children
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
12 Years to 17 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
22
States / cities
New Haven, Connecticut • Stamford, Connecticut • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Treximet Early Intervention Adolescent Migraine

NCT01016678
View directory record Official record
Conditions
Migraine
Interventions
Treximet, Placebo
Drug
Lead sponsor
Premiere Research Institute
Other
Eligibility
12 Years to 17 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
West Palm Beach, Florida • Cincinnati, Ohio • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional

A Preliminary Investigation of the Efficacy of Aromatherapy in Reducing Discomfort in Youth With Chronic Headache

NCT02440997
View directory record Official record
Conditions
Chronic Headache, Migraine Headache, Headache
Interventions
aromatherapy, foot bath
Other
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
7 Years to 17 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 9, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Real World Data Analysis: Impact of High-Frequency REN Treatments As Migraine Preventive Therapy in Adolescence

NCT05769322
View directory record Official record
Conditions
Migraine
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
12 Years to 18 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational Results available

Real-world Data Analysis of REN Treatment in Adolescence With Migraine

NCT05443659
View directory record Official record
Conditions
Migraine in Adolescence
Interventions
Nerivio
Device
Lead sponsor
Theranica
Industry
Eligibility
12 Years to 18 Years
Enrollment
1,629 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

NCT04530110
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
32
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 3 Interventional Results available

A 1-year Study in Adolescents to Assess the Long-term Safety of Almotriptan Malate When Treating Their Migraine Headaches

NCT00257010
View directory record Official record
Conditions
Migraine
Interventions
Almotriptan Malate
Drug
Lead sponsor
Janssen-Ortho LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
49
States / cities
Mobile, Alabama • Montgomery, Alabama • Oxford, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Puberty, Sex Hormones and Pain Sensitivity in Adolescents With Migraine

NCT05738213
View directory record Official record
Conditions
Migraine
Interventions
Thermal stimuli, Pressure stimuli, Pain ratings, Pressure pain thresholds (PPT), Conditioned pain modulation (CPM) response, PedMIDAS (Pediatric Migraine Disability Assessment), Hormonal assessment, Pubertal status
Device · Behavioral · Diagnostic Test + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
11 Years to 15 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional

Mindfulness-Based Intervention for Adolescents With Chronic Migraine

NCT06414109
View directory record Official record
Conditions
Migraine, Migraine in Adolescence
Interventions
BREATHE-Migraine
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
13 Years to 18 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Bringing Relief to Adolescents Naturally Using Melatonin for Migraine

NCT02344316
View directory record Official record
Conditions
Migraine in Adolescents
Interventions
Melatonin, Placebo
Drug · Other
Lead sponsor
Amy Gelfand
Other
Eligibility
12 Years to 17 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.

NCT00989625
View directory record Official record
Conditions
Migraine Disorders
Interventions
This is a pharmacokinetic study (Treximet)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
3
States / cities
Wichita, Kansas • Louisville, Kentucky • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Results available

Peer Mentorship: An Intervention To Promote Effective Pain Self-Management In Adolescents

NCT01118988
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS), Functional Abdominal Pain, Fibromyalgia, Complex Regional Pain Syndrome (CRPS), Myofacial Pain, Chronic Daily Headaches, Migraine Headaches, Chronic Pain
Interventions
Mentorship
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 18 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

NCT06616194
View directory record Official record
Conditions
Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 17 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
27
States / cities
Phoenix, Arizona • Long Beach, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting No phase listed Observational

Puberty, Testosterone, and Brain Development

NCT06670053
View directory record Official record
Conditions
Gender Identity, Gender Dysphoria in Adolescents and Adults, Headache, Transgender
Interventions
Testosterone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 20 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 17, 2026, 5:15 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

NCT04616326
View directory record Official record
Conditions
Chronic Migraine
Interventions
Galcanezumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
45
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 17, 2026, 5:15 AM EDT